Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis.

Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Abstract Text:

Jeanine D'Armiento,Kazushi Imai,John Schiltz,Natalya Kolesnekova,David Sternberg,Kathleen Benson,Annie Pardo,Moises Selman,Theresa Smolarek,Murty Vundavalli,Joshua Sonnet,Matthias Szabolcs,Kiran Chada,

The normal expression pattern of HMGA2, an architectural transcription factor, is primarily restricted to cells of the developing mesenchyme before their overt differentiation during organogenesis. A detailed in situ hybridization analysis showed that the undifferentiated mesoderm of the embryonic lung expressed Hmga2 but it was not expressed in the newborn or adult lung. Previously, HMGA2 was shown to be misexpressed in a number of benign, differentiated mesenchymal tumors including lipomas, uterine leiomyomas, and pulmonary chondroid hamartomas. Here, we show that HMGA2 is misexpressed in pulmonary lymphangiomyomatosis (LAM), a severe disorder of unknown etiology consisting of lymphatic smooth muscle cell proliferation that results in the obstruction of airways, lymphatics, and vessels. Immunohistochemistry was done with antibodies to HMGA2 and revealed expression in lung tissue samples obtained from 21 patients with LAM. In contrast, HMGA2 was not expressed in sections of normal adult lung or other proliferative interstitial lung diseases, indicating that the expression of HMGA2 in LAM represents aberrant gene activation and is not due solely to an increase in cellular proliferation. In vivo studies in transgenic mice show that misexpression of HMGA2 in smooth muscle cells resulted in increased proliferation of these cells in the lung surrounding the epithelial cells. Therefore, similar to the other mesenchymal neoplasms, HMGA2 misexpression in the smooth muscle cell leads to abnormal proliferation and LAM tumorigenesis. These results suggest that HMGA2 plays a central role in the pathogenesis of LAM and is a potential candidate as a therapeutic target.

Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Publishing Authors By Initials

J D'Armiento,K Imai,J Schiltz,N Kolesnekova,D Sternberg,K Benson,A Pardo,M Selman,T Smolarek,M Vundavalli,J Sonnet,M Szabolcs,K Chada,

For similar cells: muscle cells: myocytes, smooth muscle research abstracts see: cells: muscle cells: myocytes, smooth muscle research

PUBMED ID PMID:

MEDLINE DATE:

Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cancer research

VOLUME: 67

Page Numbers: 1902-9

Journal Abbreviation: Cancer Res.

ISSN: 0008-5472

DAY: 1

MONTH: Mar

YEAR: 2007

Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Keywords Mesh Terms:

KEYWORDS: Myocytes, Smooth Muscle

MESH TERMS: metabolism

Chemical & Substance for Abstract: Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Information

Substance Name: HMGA2 Protein

Registry Number: 0

Grant and Affiliation Information for Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis.

AFFILIATION: Department of Medicine, Surgery, and Pathology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY, USA. jmd12@columbia.edu

Country: United States

AGENCY: United States NCI

GRANT: CA 77929

ACRONYM: CA

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis Related Publications

• HMGI family proteins: architectural transcription factors in mammalian development and cancer.
• Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10.
• Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis.